Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.

scientific article published on 20 October 2017

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1182/BLOOD-2017-06-791228
P698PubMed publication ID29054911

P50authorJesús San MiguelQ5930658
Nizar J BahlisQ114442082
Ludek PourQ114442087
Helgi van de VeldeQ114442097
Dixie-Lee EsseltineQ114442105
Deborah BergQ117252347
Tamás MassziQ44908009
Peter GanlyQ56754540
Michele CavoQ57233657
Herve Avet-LoiseauQ61112732
S. Vincent RajkumarQ61123608
Shaji K KumarQ85960198
Antonio PalumboQ87013105
Paul G. RichardsonQ87712102
Philippe MoreauQ87734443
Alessandra Di BaccoQ90126524
P2093author name stringWee-Joo Chng
Christian Langer
Dina Ben-Yehuda
Jianchang Lin
Luisa Viterbo
Arnon Nagler
Andrzej Pluta
P433issue24
P407language of work or nameEnglishQ1860
P304page(s)2610-2618
P577publication date2017-10-20
P1433published inBloodQ885070
P1476titleIxazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients
P478volume130

Reverse relations

cites work (P2860)
Q101226332Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
Q91584842Hepatitis B virus infection and 1q21 amplification in multiple myeloma
Q92903027Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy
Q93086330Impact of acquired del(17p) in multiple myeloma
Q91272434Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance
Q90317855Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma
Q89992911Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost
Q64099073Management of cardiovascular risk in patients with multiple myeloma
Q47784917Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma
Q92265584Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma
Q93001945Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma
Q90244255Updates from the 2019 American Society of Clinical Oncology and European Hematology Association annual meetings: a Canadian perspective on high-risk cytogenetics in multiple myeloma

Search more.